Home / Publications / Active targeting of manganese nanoparticles for MRI contrast enhancement: prospects and challenges

Active targeting of manganese nanoparticles for MRI contrast enhancement: prospects and challenges

Share
Cite this
GOST
 | 
Cite this
GOST Copy
Faizullin B. A. et al. [{"id":"_VqQ1CGjis","type":"paragraph","data":{"text":"Active targeting of manganese nanoparticles for MRI contrast enhancement: prospects and challenges"}}] // Russian Chemical Reviews. 2025. Vol. 94. No. 10. RCR5193
GOST all authors (up to 50) Copy
Faizullin B. A., Khazieva A. R., Akhmadeev B. S., Mustafina A. R. [{"id":"_VqQ1CGjis","type":"paragraph","data":{"text":"Active targeting of manganese nanoparticles for MRI contrast enhancement: prospects and challenges"}}] // Russian Chemical Reviews. 2025. Vol. 94. No. 10. RCR5193
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.59761/RCR5193
UR - https://rcr.colab.ws/publications/10.59761/RCR5193
TI - [{"id":"_VqQ1CGjis","type":"paragraph","data":{"text":"Active targeting of manganese nanoparticles for MRI contrast enhancement: prospects and challenges"}}]
T2 - Russian Chemical Reviews
AU - Faizullin, Bulat A.
AU - Khazieva, Alsu R.
AU - Akhmadeev, Bulat S.
AU - Mustafina, Asiya R.
PY - 2025
DA - 2025/10/20
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - RCR5193
IS - 10
VL - 94
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Faizullin,
author = {Bulat A. Faizullin and Alsu R. Khazieva and Bulat S. Akhmadeev and Asiya R. Mustafina},
title = {[{"id":"_VqQ1CGjis","type":"paragraph","data":{"text":"Active targeting of manganese nanoparticles for MRI contrast enhancement: prospects and challenges"}}]},
journal = {Russian Chemical Reviews},
year = {2025},
volume = {94},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Oct},
url = {https://rcr.colab.ws/publications/10.59761/RCR5193},
number = {10},
doi = {10.59761/RCR5193}
}
MLA
Cite this
MLA Copy
Faizullin, Bulat A., et al. “[{"id":"_VqQ1CGjis","type":"paragraph","data":{"text":"Active targeting of manganese nanoparticles for MRI contrast enhancement: prospects and challenges"}}].” Russian Chemical Reviews, vol. 94, no. 10, Oct. 2025, p. RCR5193. https://rcr.colab.ws/publications/10.59761/RCR5193.
Publication views
5

Keywords

active targeting
conjugation method
magnetic relaxation
magnetic resonance imaging
manganese compounds
nanoparticles

Abstract

The growing interest in Mn2+ ions for T1-weighted contrast agents (CAs) stems from their biogenic nature, driving the development of Mn-based complexes and nanoparticles. To enhance tumor contrast and minimize side effects from retention in healthy tissues, active targeting of Mn-based CAs is crucial. Key targeting strategies for Mn2+-based CAs are reviewed alongside those for Gd3+ and iron oxide agents, as Mn2+ CAs were developed later. In this review, the main focus is on Mn-containing nanoparticles, since from the point of view of the contrast effect and limited delivery of Mn2+ ions, they are a more promising basis for CA than molecular Mn2+ complexes. Hydrophilic nanoplatforms such as triblock copolymer micelles, silica nanoparticles and protein nanoparticles are the focus of this review due to their widespread use in the design of CAs and their ability to be easily conjugated with functional groups required for active targeting. The literature examples show that the T1-weighted contrast of such nanoplatforms conjugated with targeting molecules may differ from that of unconjugated ones, since the high lability of the surface exposed Mn2+ ions promotes their redistribution due to coordination through chelating groups on the conjugated nanoplatform. However, this aspect of the development of manganese-based nanoscale contrast agents has not been sufficiently discussed in previous reviews devoted to such nanomaterials.

The bibliography includes 120 references.

1. Introduction

Although magnetic resonance imaging (MRI) is a powerful non-invasive tool in medicine, its sensitivity in contrasting cancerous tissues sometimes needs to be increased by the introduction o contrast agents (CAs). Currently known CAs are represented by both complexes of paramagnetic metal ions (Mn2+, Fe3+ and Gd3+) and their nanosized forms, represented mainly by manganese, gadolinium and iron oxides as well as metal-organic frameworks (MOFs) based on these metal ions.[1][2] Both types of contrast agents carry certain risks to living organisms, but the use of nanoparticles as CAs is a more promising direction for effective and safe contrasting of cancer tumors.[2]

The distribution of nanoparticles after their intravenous administration is organ-specific, depending on the size and nature of the nanoparticle surface.[3][4] In particular, nanoparticles larger than 100 nm are efficiently taken up by spleen macrophages and liver Kupffer cells,[5] while clearance of ultra-small (< 10 nm) nanoparticles can be accomplished by alternative mechanisms including tubular filtration[6][7] and removal by hepatocytes.[6] Both mechanisms of clearance are possible for nanoparticles between 10 and 100 nm in size, with the preferred mechanism depending on the nature of their surface.[3][4] Abnormal tumor vasculature, active angiogenesis and high vascular density and some other factors lead to passive entrance of nanoparticles through gaps between endothelial cells, which is followed by their retention in tumor tissues due to impaired lymphatic clearance, the well-known ‘enhanced permeability and retention’ effect (EPR).[8] Significant difference of diseased tissue cells from normal ones is important factor in EPR.[8] However, delivery of nanoparticles to solid tumors differs significantly from delivery to cancer cells. Thus, quantitative assessment of nanoparticle distribution in mice indicates that this effect ensures localization in tumor tissues of no more than 0.7% of the administered dose of nanoparticles.[9] In this regard, active transport and retention (ATR) has been proposed as an alternative mechanism for nanoparticle penetration into solid tumors.[10] Within this mechanism, active endothelial transport and interaction with tumor components of nanoparticles are the main reasons for their entry and retention in the tumor. Therefore, the ATR mechanism is more specific to the size and morphological features of nanoparticles than the EPR mechanism.[10] It is noteworthy that there are a large number of literature results demonstrating the tumor specificity of non-targeted nanoparticles, which in turn depends on their size, shape and surface characteristics, including the formation of the so-called protein corona.[11-16] However, the limitations imposed by these mechanisms prompt the development of the so-called active targeting approach, which is based on the introduction of certain functional groups onto the surface of nanoparticles that ensure their binding to biomolecules exposed on tumor tissues.[8] [17-20]

Indeed, both passive and active targeting should be combined to enhance tumor specificity of nanoparticles applied as drug delivery systems.[15] However, these trends can also be considered as a tool for both improving the contrast effect of nanoparticles used as CA and reducing the specific risks of these nanoparticles for living organisms due to their limited distribution in normal tissues. These trends have already been discussed for nanoparticle-based contrast agents loaded with Gd3+ and Fe3(2)+ oxides. However, the specificity of active MRI targeting using Mn2+-based nanoparticles is poorly understood, although the known features of the coordination bonds of Mn2+ ions distinguish them from Gd3+ and Fe3(2)+ ions. Therefore, this featured article will review the known synthetic conjugation approaches presented in the literature that can allow achieving specificity of penetration of Mn2+-based nanoparticles into cancer cells. Possible coordination transformations of Mn2+ ions loaded into different nanoparticles after their conjugation with target molecules will be discussed, as well as their influence on the r1 (T1-relaxivity) of these nanoparticles, which is the longitudinal magnetic relaxation rate related to one paramagnetic ion. In this work, special attention is paid to the use of commercially available and widely used chemicals in the development of such nanoparticles. Although the influence of size and shape of manganese-based nanomaterials on their relaxivity has been discussed in detail in previous reviews the challenges of developing targeted nanoscale manganese-based contrast agents have not been adequately addressed.[1][14]

2. Targeted MRI strategies developed for iron oxide nanoparticles

Since the targeting of nanosized CAs is aimed at ensuring their binding to specific receptors on cancer cells, the surface design of these CAs, leading to the incorporation of certain functional groups on their surface, has a significant impact on targeting. Literature data represent successful examples of the surface design favoring the targeting of iron-oxide nanoparticles.[8][21-24] To ensure strong binding to biomolecules exposed on the cell membranes of cancer cells, the surface of the nanoparticles is modified with proteins, hormones, biotin, folic and hyaluronic (HA) acids.[8] [25] Particular attention should be paid to the hydrophilic coating of iron oxides, that ensures their long-term circulation in the bloodstream and easy conjugation with target biomolecules. The so-called ‘PEGylation’ (covering with polyethylene glycol) of nanoparticles is a well-known and well-established approach to increase the lifetime in the bloodstream due to limiting their rapid uptake by the reticuloendothelial system.[25] Efficient hydrophilic coating of iron oxide nanoparticles can also be achieved using triblock copolymers (PEO)n(PPO)m(PEO)n, built from polyethylene oxide (PEO) and polypropylene oxide (PPO) moieties, which tend to aggregate on the surface of the nanoparticles.[26-33] Aggregates of water-soluble polymers, especially triblock copolymers (among which F68, F127 and P123 are most widely applied) and polyelectrolytes (polyethyleimines, polyaminoacids), whose molecules can be glycated or covalently modified with folic acid, biotin and oligopeptides, play a special role in the development of drug delivery systems.[18] [33-38] Targeting of such drug delivery systems is typically based on the conjugation of triblock copolymer molecules via their hydrophilic PEO block with specific functional groups to ensure their surface localization for binding to cellular receptors.[39] Variation in length of PEO and PPO blocks of triblock copolymers provides an opportunity to obtain the aggregates with diverse nanoarchitectures, including vesicular aggregates constructed from Pluronic L121 (PEO)5(PPO)68(PEO)5, which can be both efficiently conjugated with the target peptide and loaded with iron oxides.[40] Notably, the use of a triblock copolymer with different lengths of PEO fragments and their decoration with different terminal groups provides polymer vesicles with a high anticancer effect both due to loading with superparamagnetic iron oxide nanoparticles (SPIONs) and doxorubicin and due to conjugation with FA.[33] The efficiency of targeting can be visualized using in vitro fluorescence microscopy measurements. This can be achieved with bimodal nanoparticles that contain both iron ­oxide cores and organic dyes as a fluorescent component.[27][40][41]

Pluronic F127 plays a particular role in the design of drug delivery systems due to the ability of its aggregates to load a cargo and release it in an intracellular space.[41][42] It is important to note that according to literature data, the introduction of FA or peptides into triblock copolymer F127 molecules promotes the targeted delivery of iron-oxide nanoparticles into tumor tissues.[26][28][31][41] [43][44] Moreover, a hydrophilic coating of SPIONs with a triblock copolymer allows combining MRI targeting with drug delivery, which is considered a relevant area in nanomedicine.[30] [33][45-47] Together with the easy targeting of triblock copolymers, this demonstrates the importance of their use in developing of diagnostic and therapeutic iron oxide-based integration nanoplatforms. The above trends are schematically shown in the cartoon image in Fig. 1.

Fig. 1
Schematic representation of SPIONs surface hydrophilization, targeting with specific ligands and labelling with fluorescent components

The influence of the size and shape of SPIONs on their ability to contrast malignant tumors is quite significant and can be comparable to the contrast created by nanoparticles that selectively bind to specific receptors on cancer cells, or so-called targeted contrast.[11] It is also noteworthy that FA can be chelated with the surface exposed Fe3+ ions of the iron oxide nanoparticles, which also results in their targeting.[48] Nevertheless, iron oxides are usually so-called negative CAs, which manifest as tissue darkening due to the T2-contrasting effect resulted from increased transverse magnetic relaxation rates. However, the tissue brightening due to the so-called T1-contrasting effect has got wider use in medicine diagnostics. T2-contrasting effect is typical for the iron oxide nanoparticles with the size above 10 nm, whereas the small sized (about 5 nm) iron oxide nanoparticles can give higher T1-contrast compared to T2-weighted one.[49] Thus, the work [22] is noteworthy, demonstrating a nanoarchitecture where the aggregation of small sized iron oxide nanoparticles leads to T2-weighted contrast, whereas the disaggregation of these iron oxides caused by glutathione (GSH) provides selective positive T1-weighted contrast of cancer tissues due to the higher concentration of GSH in cancer cells compared to normal cells. It is noteworthy that opsonization of the SPION-based nanoarchitectures derived from the surface adsorption of serum proteins can significantly limit their targeting effectiveness.[25] Moreover, the use of SPIONs as CAs in MRI is limited due to the fact that inhomogeneous magnetic field of SPIONs can cause artifacts that reduce diagnostic accuracy, whereas T1-weighted CAs are free from this limitation. This is the reason for the considerable attention paid to nanoparticles loaded with Mn2+ and Gd3+ ions as the basis of CAs in MRI.

3. Different nanoarchitectures in the context of Mn2+ specificity

The particular interest in Mn2+-containing contrast agents (MnCAs) is due to nephrogenic drawbacks of the Gd3+-based contrast agents.[50-52] The advantage of target-mediated contrast in MRI using Gd3+-based CAs in molecular and nanoparticle forms has already been.[23][53] It is worth noting the successful techniques used for their targeting. In particular, Gd3+ ions can be doped into SPIONs, which can be coated by triblock copolymer molecules decorated with FA.[54] The work [23] demonstrates dual targeting with peptides of the dendrimer bound with Gd3+ ions as a route to get better accumulation in tumors compared to monotargeted analogs. However, the low r1 values estimated for Gd3+ ions bound with the dendrimer indicate insufficient constraint on their internal motion.[23] The work[55] demonstrates the successful creation of dual targeting CAs by covalent introduction of gadolinium chelate complex, fluorophore and targeting group into poly-lysine molecules, but the r1 value of this molecules is also on the level of molecular CAs, such as Omniskan, Gadovist and others (below 10 mM–1 s–1). The work[56] (Fig. 2) demonstrates specific nanoarchitecture constructed from the mixed assembly of the triblock copolymers F127 and P123 terminated with either folates (FA) or bovine serum albumin (BSA). The triblock copolymers terminated with BSA provide the tight binding of Gd3+ ions, while FA-terminated triblock copolymer molecules ensure the target-mediated cancer specificity.

Fig. 2
Schematic representation of micellar contrast agents’ development from the triblock copolymers conjugated with FA receptor-targeted ligands

Turning to manganese-based contrast agents, it is worth noting that the high kinetic lability and insufficient thermodynamic stability of Mn2+ complexes represent a challenge when using coordination of paramagnetic ions by polydentate ligand molecules as an approach to creating CAs.[51] Moreover, the specificity of the electronic structure of Mn2+ ions, which have only five unpaired electrons, as opposed to seven for Gd3+, is the reason for lower T1-relaxivity for Mn2+ complexes compared to Gd3+ complexes.[50-52] These drawbacks can be minimized within the nanotechnological approach to the creation of Mn2+-containing CAs by tuning parameters such as the retention time of inner-sphere water molecules and the rotational and translational motion rates of paramagnetic ions, as clearly demonstrated in the relevant reviews.[1][51][57-60] To appreciate the advantage of using nanoparticles instead of molecular complexes as CAs, it should be noted that the r1 values of commercial Mn-based molecular CAs are in the range of 2.8 – 8.0 mM−1 s−1 at 20 MHz,[51][61][62] while these values for Mn-containing nanoparticles are typically far above 10 mM−1 s−1, with the top values above 50 mM−1 s−1.[1][49][59][63][64] In this regard, the work[65] exemplifies both the use of MnFe2O4 nanocrystals instead of the iron oxides and HA-mediated targeting of breast cancer cells via binding with CD44 antigen, which is a cell-surface glycoprotein. In this case, the incorporation of aminated Polyoxyethylene (80) sorbitan monooleate conjugated with HA into the hydrophilic coating of MnFe2O4 provides both long-term circulation in the bloodstream and the targeting function. The literature data represent successful use of F127 for hydrophilic coating of Mn-loaded nanoparticles based on manganese oxides or MOF-nanocrystals based on Mn2+ complexes.[63] [66][67] Notably, F127 molecules are readily conjugated with functional groups required for targeting, although this strategy is underrepresented in the literature for Mn-based nanoparticles.

Surface-exposed silanol groups both play a major role in the cytotoxicity of silica nanoparticles (SNs) and open up wide opportunities for their covalent modification with amino or carboxyl groups, thus, providing a good basis for a targeting of SNs.[68] Thus, the doping of SNs with a wide range of d-f-metal ions, complexes or organic compounds along with their targeting is actively used in the creation of targeted theranostic systems (Fig. 3).[68-75] Mesoporous SNs play a special role in the creation of drug delivery systems and this type of SNs is represented by various sizes of both the nanoparticles and their pores.[76-78] In this regard, it is worth noting the reports that emphasize that the porosity of rather small SNs with sizes of 30 – 50 nm is sufficient for efficient hydration of manganese ions incorporated into the silica matrix when these Mn-doped SNs are synthesized by the water-in-oil microemulsion method using Triton X-100 or Igepal CO-520.[79][80] Such porosity is provided by molecules or aggregates of these non-ionic surfactants, which are adsorbed on the silica surface during synthesis, leaving pores when they are further washed out of the silica nanoparticles. Moreover, the incorporation of manganese chelates into SNs using a water-in-oil microemulsion method with Igepal CO-520, in addition to achieving much higher r1 values than for molecular complexes, demonstrates target-mediated selectivity in tumor tissue MRI contrast due to folate (FA) targeting.[80]

Fig. 3
Loading of silica nanoparticles with various metal ions or complexes, fluorescent components mainly represented by organic dyes and targeting with specific ligands

Manganese ions are inferior to gadolinium ions in terms of coordination efficiency, which, together with the high lability of their complexes, facilitates the leaching of manganese ions from the corresponding nanoparticles in solutions of increased acidity or due to their coordination with phosphate ions. Literature results including the design of stimuli-responsive Mn-loaded nanoparticles and nanoarchitectures obtained using the so-called Kirkendall effect illustrate the above trends (FIg. 4).[81-85] The easy leaching of Mn2+ ions from various Mn-containing nanoparticles makes it necessary to take into account the coordinating ability of functional groups conjugated to the nanoparticle surface, since some of them, such as folates (FA) or peptides, can initiate the leaching of Mn2+ ions. In this case, part of the loaded Mn2+ ions can be relocated from the surface of nanoparticles to these functional groups. This should be followed by changes in the hydration numbers of these Mn2+ ions, which can lead to changes in both r1 and r2/r1 values, since the latter are specifically dependent on the hydration number of the Mn2+ ions.[86][87] Notably, some reports on Mn-containing nanoparticles show an increase in r1 values after their conjugation with FA or after adsorption of serum albumins onto their surface.[80] [88] However, the coordination aspects of the change in relaxivity values after both covalent and non-covalent decoration of the surface of Mn-containing nanoparticles still await detailed discussion.

FIg. 4
Schematic illustration of the Kirkendall effect

4. Nanoarchitectures of Mn-based CAs with high biocompatibility and biodegradability

While highlighting the diversity of stimuli-responsive nanoarchitectures based on SNs suitable for biomedical use, their slow clearance and long-term localization in the liver should also be noted.[75] [89] Since the in vivo toxicity of SNs is significant only when administered in high doses,[90] the toxic effect can be limited by administering lower doses, which in turn can be achieved by creating Mn-doped SNs with high ­T1-contrast effect. Moreover, the creation of biodegradable silica-based nanoarchitectures [78] represents an alternative way to address the toxicity problem. In this regard, the use of protein molecules as building blocks of nanoarchitectures provide a good basis for the creation of biodegradable nanoparticulate CAs.

Serum albumins are the most common and cheapest base for creating a hydrophilic shell for nanoparticles, which has been successfully demonstrated on titanium and iron oxides, and the possibility of combining with the transport function of serum albumin towards drug molecules and/or organic dyes has also been shown.[91-101] Of course, bovine serum albumin (BSA) is the cheapest and most abundant, so it is more widely used than other serum albumins. Importantly, amino groups exposed on the surface of BSA can be conjugated with such targeting molecules as biotin [97][98] and FA.[99-101] Typically, the synthesis of BSA-based nanoparticles occurs by denaturing BSA molecules followed by their cross-linking. Moreover, denatured BSA molecules can be used in creating hydrophilic biodegradable shells on a surface of inorganic nanoparticles due to the high affinity of denatured BSA to nanoparticle surfaces. This makes BSA a good alternative to artificial polymers in the development of therapeutic agents [102-104] or biosensors.[105][106]Acidification-induced swelling of BSA molecules mediates drug release from BSA-based nanostructures, making them a promising platform for lysosome-mediated drug delivery.[107] In turn, the BSA-based coating of manganese-doped copper selenide nanoparticles[108] or manganese-doped iron oxide nanoparticles[109] favors their use as CAs in MRI along with the therapeutic function.

An excellent example of covalent grafting of human serum albumin (HSA) with diethylenetriaminepentaacetic acid (DTPA) ligand followed by coordination of Gd3+ ions, resulting in ­T1-weighted relaxivity, is worth noting.[96]However, the contrast effect of Gd3+ ions bound to DTPA residues grafted onto HSA is similar to that achieved by the Gd-DTPA complex in solution, indicating that the internal motion of the Gd-DTPA complex is not significantly restricted by its grafting onto the HSA nanoplatform.[96] However, it is worth noting the possibility of the tight binding of d- and f-metal to the specific binding site (binding site VI) of BSA, which provides its transport function towards transition metal ions.[110]The tight binding of metal complexes to BSA molecules is manifested in significant changes in the spectral properties of the complexes, which are caused by the limited vibrational motion of the complex molecules localized in specific BSA binding sites.[111]Thus, it is to be expected that these types of binding can provide a significant slowing of the internal motion of paramagnetic ions necessary for high T1 relaxivity, which follows from the high levels of T1 and T2 relaxivity of manganese ions in BSA solutions.[112][113] It is noteworthy that the literature data provide the series of the well-developed approaches to convert native serum albumins into the albumin-based nanoparticles, which have been shown to serve as drug delivery systems.[114]Relatively recently, it has been shown that the efficiency of such binding persists even after partial denaturation of BSA, further crosslinking of which allows the formation of Mn2+-containing nanoparticles with high T1 and T2 relaxivities (Fig. 5).[115]It has been shown that the molar ratio Mn : BSA should be kept at a level of 4 : 1 for high negative surface charge required for high colloidal stability of BSA-based nanoparticles loaded with Mn2+ ions.[115]For the best of our knowledge, there are very few papers focused on the loading of manganese ions through their coordinative binding with protein-based nanoplatform, although there are enough papers on the loading of copper ions into BSA-based nanoarchitectures.[116-120] These copper-containing nanoarchitectures are in the spotlight due to their laccase-like enzymatic activity,[116-118] whereas the Mn-loaded BSA-based nanoparticles exhibit antioxidant properties.[115]All this makes Mn-loaded BSA-based nanoparticles convenient basis for development of targeted CAs.

Fig. 5
Schematic representation of high contrasting Mn2+ containing BSA nanoparticles synthesis

5. Prospects and conclusions

In summary, targeting methods well developed for drug delivery systems have been successfully used to enhance contrast effect of iron-oxide nanoparticles under their use as contrast agents, while the examples of targeted Mn2+-containing contrast agents are clearly insufficient. Numerous examples in the literature show that the use of triblock copolymers and serum albumins for hydrophilic coating of inorganic nanoparticles is a promising tool for creating targeted contrast, since they provide easy conjugation with functional groups. However, their application for creating Mn-containing nanoparticles with targeted contrast has not yet been studied. The targeted Mn-loaded nanoparticles conjugated through silanol groups have been represented as very successful example due to the additional raising in T1 relaxivity after the conjugation with folates (FA). However, a deeper understanding of the reasons for this trend is still awaited. Notably, the active targeting of Mn-containing nanoparticles can be largely overlapped by the EPR and ATR effects when these nanoparticles are used in living organisms. Therefore, different target-induced contrast effect can be expected for nanoparticles with different sizes, shapes and surface properties. The relationship between the active targeting effects and the morphological specificity of manganese nanoparticles needs to be studied both in vitro using standard cancer and normal cell lines and in vivo using MRI studies in living mice.

Acknowledgements

This research was funded by Russian Science Foundation (grant number 22-13-00010 П).

References

1.
Recent progress in design and surface modification of manganese nanoparticles for MRI contrasting and therapy
Zairov R.R., Akhmadeev B.S., Fedorenko S.V., Mustafina A.R.
Chemical Engineering Journal, Elsevier, 2023
2.
Manganese‐Enhanced MRI Contrast Agents: From Small Chelates to Nanosized Hybrids
Kueny‐Stotz M., Garofalo A., Felder‐Flesch D.
European Journal of Inorganic Chemistry, Wiley, 2012
3.
Nanoscopic Agents in a Physiological Environment: The Importance of Understanding Their Characteristics
Sherwood V., Di Silvio D., Baldelli Bombelli F.
Topics in Medicinal Chemistry, Springer Nature, 2013
4.
Nanoparticle-blood interactions: the implications on solid tumour targeting.
Lazarovits J., Chen Y.Y., Sykes E.A., Chan W.C.
Chemical Communications, Royal Society of Chemistry (RSC), 2015
5.
Kupffer cells are central in the removal of nanoparticles from the organism
Sadauskas E., Wallin H., Stoltenberg M., Vogel U., Doering P., Larsen A., Danscher G.
Particle and Fibre Toxicology, Springer Nature, 2007
6.
Renal clearance of quantum dots
Soo Choi H., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., Bawendi M.G., Frangioni J.V.
Nature Biotechnology, Springer Nature, 2007
7.
Dendrimer-Based Nanosized MRI Contrast Agents
Kobayashi H., Brechbiel M.
Current Pharmaceutical Biotechnology, Bentham Science Publishers Ltd., 2004
8.
Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications
Ahmad J., Rizwanullah M., Suthar T., Albarqi H.A., Ahmad M.Z., Vuddanda P.R., Khan M.A., Jain K.
Critical Reviews in Therapeutic Drug Carrier Systems, Begell House, 2022
9.
EPR: Evidence and fallacy.
Nichols J.W., Bae Y.H.
Journal of Controlled Release, Elsevier, 2014
10.
The mechanisms of nanoparticle delivery to solid tumours
Nguyen L.N., Ngo W., Lin Z.P., Sindhwani S., MacMillan P., Mladjenovic S.M., Chan W.C.
Nature Reviews Bioengineering, Springer Nature, 2024
11.
Biodistribution and Tumors MRI Contrast Enhancement of Magnetic Nanocubes, Nanoclusters, and Nanorods in Multiple Mice Models
Naumenko V., Garanina A., Nikitin A., Vodopyanov S., Vorobyeva N., Tsareva Y., Kunin M., Ilyasov A., Semkina A., Chekhonin V., Abakumov M., Majouga A.
Contrast Media and Molecular Imaging, Hindawi Limited, 2018
12.
Why Do Lipid Nanoparticles Target the Liver? Understanding of Biodistribution and Liver-Specific Tropism
Hosseini-Kharat M., Bremmell K.E., Prestidge C.A.
Molecular Therapy - Methods and Clinical Development, Elsevier, 2025
13.
Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy
Austria E., Bilek M., Varamini P., Akhavan B.
Nano Today, Elsevier, 2025
14.
The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction.
Hoshyar N., Gray S., Han H., Bao G.
Nanomedicine, Taylor & Francis, 2016
15.
Nanomedicine for ovarian cancer: Enhancing pharmacokinetics and biodistribution
Saddick S.
Journal of King Saud University - Science, Elsevier, 2024
16.
The role of patient-specific variables in protein corona formation and therapeutic efficacy in nanomedicine
Cisneros E.P., Morse B.A., Savk A., Malik K., Peppas N.A., Lanier O.L.
Journal of Nanobiotechnology, Springer Nature, 2024
17.
Application of Non-Viral Vectors in Drug Delivery and Gene Therapy
Ren S., Wang M., Wang C., Wang Y., Sun C., Zeng Z., Cui H., Zhao X.
Polymers, MDPI, 2021
18.
Pluronics and MDR Reversal: An Update
Alakhova D.Y., Kabanov A.V.
Molecular Pharmaceutics, American Chemical Society (ACS), 2014
20.
Nanotheranostics for Diagnosis and Treatment of Breast Cancer
Jain K., R. Patel P., Kumar K., K. Jain V., Popli H., K. Yadav A.
Current Pharmaceutical Design, Bentham Science Publishers Ltd., 2023
21.
Physico-chemical and toxicological characterization of iron-containing albumin nanoparticles as platforms for medical imaging
Rosenberger I., Schmithals C., Vandooren J., Bianchessi S., Milani P., Locatelli E., Israel L.L., Hübner F., Matteoli M., Lellouche J., Franchini M.C., Passoni L., Scanziani E., Opdenakker G., Piiper A., et. al.
Journal of Controlled Release, Elsevier, 2014
22.
Extremely Small Iron Oxide Nanoparticle-Encapsulated Nanogels as a Glutathione-Responsive T1 Contrast Agent for Tumor-Targeted Magnetic Resonance Imaging
Cao Y., Mao Z., He Y., Kuang Y., Liu M., Zhou Y., Zhang Y., Pei R.
ACS applied materials & interfaces, American Chemical Society (ACS), 2020
23.
Synergetic Enhancement of Tumor Double-Targeted MRI Nano-Probe
Yabbarov N., Nikolskaya E., Sokol M., Mollaeva M., Chirkina M., Seregina I., Gulyaev M., Pirogov Y., Petrov R.
International Journal of Molecular Sciences, MDPI, 2022
24.
Carboxymethyl-sagocellulose-stabilized Fe3O4 nanoparticles with 5-fluorouracil as photothermal agents for tumor ablation
Veeramachineni A.K., Sathasivam T., Paramasivam R., Muniyandy S., Khamis S.B., Lim Y.Y., Pushpamalar J.
Cancer Nanotechnology, Springer Nature, 2024
25.
Magnetic nanoparticle design for medical diagnosis and therapy
Mornet S., Vasseur S., Grasset F., Duguet E.
Journal of Materials Chemistry A, Royal Society of Chemistry (RSC), 2004
27.
Biocompatible magnetic hydroxyapatite Fe3O4-HAp nanocomposites for T1-magnetic resonance imaging guided photothermal therapy of breast cancer
Mushtaq A., Tang Z., Hou Y., Zhu Z., Tian C., Wu Y., Lu Y., Iqbal M.Z., Kong X.
Materials Today Communications, Elsevier, 2022
28.
Folic acid modified Fe3O4 nanoclusters by a one-step ultrasonic technique for drug delivery and MR imaging
Fei M., Song M., Wang P., Pang G., Chen J., Lu D., Liu R., Zhang G., Zhao T., Shen Y., Yu Y.
RSC Advances, Royal Society of Chemistry (RSC), 2020
29.
Controlled temperature-mediated curcumin release from magneto-thermal nanocarriers to kill bone tumors
Khodaei A., Jahanmard F., Madaah Hosseini H.R., Bagheri R., Dabbagh A., Weinans H., Amin Yavari S.
Bioactive Materials, Elsevier, 2022
30.
MRI Guided Magneto-chemotherapy with High-Magnetic-Moment Iron Oxide Nanoparticles for Cancer Theranostics
Salunkhe A., Khot V., Patil S.I., Tofail S.A., Bauer J., Thorat N.D.
ACS Applied Bio Materials, American Chemical Society (ACS), 2020
31.
Peptide-Decorated Ultrasmall Superparamagnetic Nanoparticles as Active Targeting MRI Contrast Agents for Ovarian Tumors
Yin J., Yao D., Yin G., Huang Z., Pu X.
ACS applied materials & interfaces, American Chemical Society (ACS), 2019
32.
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting
Chen K., Xie J., Xu H., Behera D., Michalski M.H., Biswal S., Wang A., Chen X.
Biomaterials, Elsevier, 2009
33.
Multifunctional Stable and pH-Responsive Polymer Vesicles Formed by Heterofunctional Triblock Copolymer for Targeted Anticancer Drug Delivery and Ultrasensitive MR Imaging
Yang X., Grailer J.J., Rowland I.J., Javadi A., Hurley S.A., Matson V.Z., Steeber D.A., Gong S.
ACS Nano, American Chemical Society (ACS), 2010
34.
Triblock Copolymer-Encapsulated Nanoparticles with Outstanding Colloidal Stability for siRNA Delivery
Qian J., Gao X.
ACS applied materials & interfaces, American Chemical Society (ACS), 2013
35.
Theory of Block Polymer Micelles: Recent Advances and Current Challenges
Zhulina E.B., Borisov O.V.
Macromolecules, American Chemical Society (ACS), 2012
37.
Targeting anticancer drugs with pluronic aggregates: Recent updates
Tiwari S., Kansara V., Bahadur P.
International Journal of Pharmaceutics, Elsevier, 2020
38.
Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy
40.
Continuously manufactured magnetic polymersomes – a versatile tool (not only) for targeted cancer therapy
Bleul R., Thiermann R., Marten G.U., House M.J., Pierre T.G., Häfeli U.O., Maskos M.
Nanoscale, Royal Society of Chemistry (RSC), 2013
42.
Physico-chemical properties of meso-tetrakis(p-methoxyphenyl)porphyrin (TMPP) incorporated into pluronicTM p-123 and f-127 polymeric micelles
Vilsinski B.H., Aparicio J.L., Pereira P.C., Fávaro S.L., Campanholi K.S., Gerola A.P., Tessaro A.L., Hioka N., Caetano W.
Quimica Nova, SciELO, 2014
43.
J.Gao. Chin. J. Tissue Eng. Res., 24, 4526 (2020)
44.
Pluronic F127-Folate Coated Super Paramagenic Iron Oxide Nanoparticles as Contrast Agent for Cancer Diagnosis in Magnetic Resonance Imaging
Vu-Quang H., Vinding M.S., Nielsen T., Ullisch M.G., Nielsen N.C., Nguyen D., Kjems J.
Polymers, MDPI, 2019
45.
Magnetite nanocluster and paclitaxel-loaded charge-switchable nanohybrids for MR imaging and chemotherapy
Wu L., Wu M., Lin X., Zhang X., Liu X., Liu J.
Journal of Materials Chemistry B, Royal Society of Chemistry (RSC), 2017
46.
Contrasting Properties of Polymeric Nanocarriers for MRI-Guided Drug Delivery
48.
Assessment of the in Vitro Effects of Folate Core–Shell Conjugated Iron Oxide Nanoparticles as a Potential Agent for Acute Leukemia Treatment
El Hamshary M.O., Moawad M., Talaat R.M., Thawabieh O.M., Nasr G.M.
Frontiers in Bioscience-Landmark, IMR Press, 2024
49.
Factors controlling the organ-specific T1 contrast effect of silica nanoparticles co-doped with both Mn2+ ions and oleate-coated iron oxides.
Bochkova O., Stepanov A., Bebyakina A., Smekalov D., Kholin K., Nizameev I., Romashchenko A., Zavjalov E., Lubina A., Voloshina A., Tyapkina O., Tarasov M., Sultanov T., Rümmeli M., Salnikov V., et. al.
Journal of Alloys and Compounds, Elsevier, 2024
50.
Revisiting an old friend: manganese-based MRI contrast agents
Pan D., Caruthers S.D., Senpan A., Schmieder A.H., Wickline S.A., Lanza G.M.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Wiley, 2010
51.
Manganese-based MRI contrast agents: past, present, and future
Pan D., Schmieder A.H., Wickline S.A., Lanza G.M.
Tetrahedron, Elsevier, 2011
52.
Manganese(II) Complexes as Potential Contrast Agents for MRI
Drahoš B., Lukeš I., Tóth É.
European Journal of Inorganic Chemistry, Wiley, 2012
53.
Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents
Koudrina A., DeRosa M.C.
ACS Omega, American Chemical Society (ACS), 2020
54.
Anisotropic Gold Nanoparticle Decorated Magnetopolymersome: An Advanced Nanocarrier for Targeted Photothermal Therapy and Dual-Mode Responsive T1 MRI Imaging
56.
Controlled design and construction of multifunctional nanoparticles by molecular self-assembly
Suthiwangcharoen N., Nagarajan R.
RSC Advances, Royal Society of Chemistry (RSC), 2014
58.
Mn(II) compounds as an alternative to Gd-based MRI probes
Botta M., Carniato F., Esteban-Gómez D., Platas-Iglesias C., Tei L.
Future Medicinal Chemistry, Taylor & Francis, 2019
59.
Manganese complexes and manganese-based metal-organic frameworks as contrast agents in MRI and chemotherapeutics agents: Applications and prospects
Zheng R., Guo J., Cai X., Bin L., Lu C., Singh A., Trivedi M., Kumar A., Liu J.
Colloids and Surfaces B: Biointerfaces, Elsevier, 2022
60.
Research Advance in Manganese Nanoparticles in Cancer Diagnosis and Therapy
Nie D., Zhu Y., Guo T., Yue M., Lin M.
Frontiers in Materials, Frontiers Media S.A., 2022
61.
Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths
Rohrer M., Bauer H., Mintorovitch J., Requardt M., Weinmann H.
Investigative Radiology, Ovid Technologies (Wolters Kluwer Health), 2005
62.
Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T
Szomolanyi P., Rohrer M., Frenzel T., Noebauer-Huhmann I.M., Jost G., Endrikat J., Trattnig S., Pietsch H.
Investigative Radiology, Ovid Technologies (Wolters Kluwer Health), 2019
63.
Specificity of hexarhenium cluster anions for synthesis of Mn2+-based nanoparticles with lamellar shape and pH-induced leaching for specific organ selectivity in MRI contrasting
Akhmadeev B.S., Nizameev I.R., Kholin K.V., Voloshina A.D., Gerasimova T.P., Gubaidullin A.T., Romashchenko A.V., Zavjalov E.L., Kashnik I.V., Brylev K.A., Mustafina A.R.
Journal of Colloid and Interface Science, Elsevier, 2024
65.
Efficient CD44-targeted magnetic resonance imaging (MRI) of breast cancer cells using hyaluronic acid (HA)-modified MnFe2O4 nanocrystals
Lee T., Lim E., Lee J., Kang B., Choi J., Park H.S., Suh J., Huh Y., Haam S.
Nanoscale Research Letters, Springer Nature, 2013
66.
Molecular and Nano-Structural Optimization of Nanoparticulate Mn2+-Hexarhenium Cluster Complexes for Optimal Balance of High T1- and T2-Weighted Contrast Ability with Low Hemoagglutination and Cytotoxicity
Akhmadeev B.S., Nizameev I.R., Kholin K.V., Voloshina A.D., Gerasimova T.P., Gubaidullin A.T., Kadirov M.K., Ismaev I.E., Brylev K.A., Zairov R.R., Mustafina A.R.
Pharmaceutics, MDPI, 2022
67.
A facile fabrication route for binary transition metal oxide-based Janus nanoparticles for cancer theranostic applications
Iqbal M.Z., Ren W., Saeed M., Chen T., Ma X., Yu X., Zhang J., Zhang L., Li A., Wu A.
Nano Research, Springer Nature, 2018
68.
Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics
Dutta Gupta Y., Mackeyev Y., Krishnan S., Bhandary S.
Cancer Nanotechnology, Springer Nature, 2024
69.
Mesoporous silica nanoparticles functionalized with folic acid for targeted release Cis-Pt to glioblastoma cells
Ortiz-Islas E., Sosa-Arróniz A., Manríquez-Ramírez M.E., Rodríguez-Pérez C.E., Tzompantzi F., Padilla J.M.
Reviews on Advanced Materials Science, Walter de Gruyter, 2021
70.
A pH-sensitive drug delivery system based on folic acid-targeted HBP-modified mesoporous silica nanoparticles for cancer therapy
Li Y., Wang S., Song F.X., Zhang L., Yang W., Wang H.X., Chen Q.L.
Colloids and Surfaces A: Physicochemical and Engineering Aspects, Elsevier, 2020
72.
Functional surface modifications impact on the in vitro/in vivo toxicity and intracellular internalization behavior of mesoporous silica nanoparticles
Ji Y., Lv R., Wang H., Gao S., Hao N., Yan Y., Gao X., Zhang Q., Han X., Cao M.
Colloids and Surfaces A: Physicochemical and Engineering Aspects, Elsevier, 2024
73.
Hyaluronic Acid-Coated Silica Nanoparticles for Targeted Delivery of Nitric Oxide to Cancer Cells
Grayton Q.E., Phan T.T., Kussatz C.C., Schoenfisch M.H.
ACS Applied Bio Materials, American Chemical Society (ACS), 2024
74.
Polymeric functionalization of mesoporous silica nanoparticles: Biomedical insights
Nair A., Chandrashekhar H. R., Day C.M., Garg S., Nayak Y., Shenoy P.A., Nayak U.Y.
International Journal of Pharmaceutics, Elsevier, 2024
75.
Nanoengineered silica: Properties, applications and toxicity
Mebert A.M., Baglole C.J., Desimone M.F., Maysinger D.
Food and Chemical Toxicology, Elsevier, 2017
76.
Mesoporous silica nanoparticles: A Synthesis Guide and Research Progress in the Biomedical Field
Chen J., Xu Z., Zhang M., Ju Z., Niu Z., Ma Y., Xu Z., Zhang T., Shi F.
Materials Today Chemistry, Elsevier, 2024
77.
Current trends in silica based drug delivery systems
Khoz R., Yazdian F., Pourmadadi M., Rahdar A., Fathi-karkan S., Pandey S.
European Journal of Medicinal Chemistry Reports, Elsevier, 2024
78.
In situ modified mesoporous silica nanoparticles: synthesis, properties and theranostic applications
Trayford C., van Rijt S.
Biomaterials Science, Royal Society of Chemistry (RSC), 2024
79.
Magnetic relaxation of various silica-based Mn-contrast agents in relationship with Mn2+ chemical transformations during fabrication
Bochkova O., Stepanov A., Khazieva A., Akhmadeev B., Ismaev I., Kholin K., Nizameev I., Sapunova A., Voloshina A., Laskin A., Smekalov D., Tarasov M., Budnikova Y., Mustafina A.
Materials Today Chemistry, Elsevier, 2023
81.
82.
Chemical design of nanoprobes for T1-weighted magnetic resonance imaging
83.
Honeycomb-Satellite Structured pH/H2O2-Responsive Degradable Nanoplatform for Efficient Photodynamic Therapy and Multimodal Imaging
Sun Q., He F., Sun C., Wang X., Li C., Xu J., Yang D., Bi H., Gai S., Yang P.
ACS applied materials & interfaces, American Chemical Society (ACS), 2018
84.
A Hybrid Silica Nanoreactor Framework for Encapsulation of Hollow Manganese Oxide Nanoparticles of Superior T1Magnetic Resonance Relaxivity
Hsu B.Y., Ng M., Zhang Y., Wong S.Y., Bhakoo K., Li X., Wang J.
Advanced Functional Materials, Wiley, 2015
86.
Direct Measurement of the Mn(II) Hydration State in Metal Complexes and Metalloproteins through 17O NMR Line Widths
Gale E.M., Zhu J., Caravan P.
Journal of the American Chemical Society, American Chemical Society (ACS), 2013
87.
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1contrast agents
Caravan P., Farrar C.T., Frullano L., Uppal R.
Contrast Media and Molecular Imaging, Hindawi Limited, 2009
88.
Adsorption of denatured BSA on bare Mn2+-doped silica nanoparticles as a tool for altering magnetic relaxation parameters and hemocompatibility
Bochkova O., Bebyakina A., Akhmadeev B., Stepanov A., Khamatgalimov A., Nizameev I., Kholin K., Abakumov M., Lubina A., Voloshina A., Mukhametzyanov T., Amirov R., Mustafina A.
Materials Chemistry and Physics, Elsevier, 2025
89.
Synthetic amorphous silica nanoparticles: toxicity, biomedical and environmental implications
Croissant J.G., Butler K.S., Zink J.I., Brinker C.J.
Nature Reviews Materials, Springer Nature, 2020
90.
Toxicology of silica nanoparticles: an update
Murugadoss S., Lison D., Godderis L., Van Den Brule S., Mast J., Brassinne F., Sebaihi N., Hoet P.H.
Archives of Toxicology, Springer Nature, 2017
92.
Temperature-Induced Denaturation of BSA Protein Molecules for Improved Surface Passivation Coatings
Park J.H., Jackman J.A., Ferhan A.R., Ma G.J., Yoon B.K., Cho N.
ACS applied materials & interfaces, American Chemical Society (ACS), 2018
93.
Nanoscale surface curvature modulates nanoparticle-protein interactions
Xia Z., Villarreal E., Wang H., Lau B.L.
Colloids and Surfaces B: Biointerfaces, Elsevier, 2020
94.
Study of protein encapsulated manganite nanoparticles for magnetic Hyperthermia
Khan A.S., Nasir M.F., Murtaza A.
Physica B: Condensed Matter, Elsevier, 2023
96.
Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging
Watcharin W., Schmithals C., Pleli T., Köberle V., Korkusuz H., Huebner F., Zeuzem S., Korf H.W., Vogl T.J., Rittmeyer C., Terfort A., Piiper A., Gelperina S., Kreuter J.
European Journal of Pharmaceutics and Biopharmaceutics, Elsevier, 2014
97.
Biotin-modified bovine serum albumin nanoparticles as a potential drug delivery system for paclitaxel
Wang D., Liang N., Kawashima Y., Cui F., Yan P., Sun S.
Journal of Materials Science, Springer Nature, 2019
99.
Folic acid conjugated bovine serum albumin: An efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells
Nosrati H., Abbasi R., Charmi J., Rakhshbahar A., Aliakbarzadeh F., Danafar H., Davaran S.
International Journal of Biological Macromolecules, Elsevier, 2018
100.
Folic acid-modified bovine serum albumin nanoparticles with doxorubicin and chlorin e6 for effective combinational chemo-photodynamic therapy
Lee H., Kim S., Oh C., Khan I., Shukla S., Bajpai V.K., Han Y., Huh Y.S.
Materials Science and Engineering C, Elsevier, 2020
101.
A pH/GSH Dual‐Responsive, Folic Acid Targeted Drug Delivery System Based on Bovine Serum Albumin Nanoparticles for Cancer Therapy
Xiong B., Liu H., Yi M., Li Y., Huang Y., Guo W., Lin Y., Liu P., Lu B.
Particle and Particle Systems Characterization, Wiley, 2024
103.
Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo
Yang R., TANG Q., AN Y., Miao F., Liu P., Li M.
International Journal of Nanomedicine, Taylor & Francis, 2014
104.
Synthesis and Application of Albumin Nanoparticles Loaded with Prussian Blue Nanozymes
Khramtsov P., Kropaneva M., Bochkova M., Timganova V., Kiselkov D., Zamorina S., Rayev M.
Colloids and Interfaces, MDPI, 2022
105.
Protein-Directed Synthesis of Mn-Doped ZnS Quantum Dots: A Dual-Channel Biosensor for Two Proteins
Wu P., Zhao T., Tian Y., Wu L., Hou X.
Chemistry - A European Journal, Wiley, 2013
106.
Dopamine-induced photoluminescence quenching of bovine serum albumin–capped manganese-doped zinc sulphide quantum dots
Abha K., Sumithra I.S., Suji S., Anjana R.R., Anjali Devi J.S., Nebu J., Lekha G.M., Aparna R.S., George S.
Analytical and Bioanalytical Chemistry, Springer Nature, 2020
107.
Z.Niazi, M.Ashjari. J. Nanostruct., 13, 382 (2023)
109.
Manganese doped iron oxide theranostic nanoparticles for combined T1 magnetic resonance imaging and photothermal therapy.
Zhang M., Cao Y., Wang L., Ma Y., Tu X., Zhang Z.
ACS applied materials & interfaces, American Chemical Society (ACS), 2015
110.
Structure of Serum Albumin
Carter D.C., Ho J.X.
Advances in Protein Chemistry, Elsevier, 1994
111.
Noncovalent interactions of antitumor cycloplatinated complexes containing trifluoroacetate ligands as the leaving group with bovine serum albumin. Implications for drug design
Aseman M.D., Negaresh P., Shojaeifard Z., Hemmateenejad B., Nabavizadeh S.M.
New Journal of Chemistry, Royal Society of Chemistry (RSC), 2023
113.
1H and17O relaxometric investigations of the binding of Mn(II) ion to human serum albumin
Aime S., Canton S., Geninatti Crich S., Terreno E.
Magnetic Resonance in Chemistry, Wiley, 2001
114.
Albumin-based delivery systems: Recent advances, challenges, and opportunities
Murphy G., Brayden D.J., Cheung D.L., Liew A., Fitzgerald M., Pandit A.
Journal of Controlled Release, Elsevier, 2025
115.
Expanding Mn2+ loading capacity of BSA via mild non-thermal denaturing and cross-linking as a tool to maximize the relaxivity of water protons
Zairov R.R., Kornev T.A., Akhmadeev B.S., Dovzhenko A.P., Vasilyev V.A., Kholin K.V., Nizameeva G.R., Ismaev I.E., Mukhametzyanov T.A., Liubina А.P., Voloshina A.D., Mustafina A.R.
International Journal of Biological Macromolecules, Elsevier, 2024
116.
Protein-derived antibacterial antioxidant nanoenzyme for fruit preservation
Zhang C., Chen H., Feng J., Wang T., Liang Y., Du T., Guo Z., Xia Y., Wang J., Zhang W.
Chemical Engineering Journal, Elsevier, 2024
117.
Cu-Albumin Artificial Enzymes with Peroxidase and Oxidase Activity for Stereoselective Oxidations
Liaqat M., McDonald E., Ortega R.J., Lopes A., Codreanu F., Carlisle H., Kumar C.V., Yao X., Rusling J.F., He J.
ACS Catalysis, American Chemical Society (ACS), 2024
119.
Enhanced glutathione sensing in clinical samples with Bovine Serum Albumin-stabilized copper nanoclusters: A novel fluorescent probe
Ragab S.M., Aboelnga M.M., Moawed E.A., Elsadda R.R., Khairy G.M.
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, Elsevier, 2025
120.
A copper complex receptor for nanomolar sulfide sensing and applications in DNA/BSA binding
Das D., Roy A., Souza C.P., Mondal S., Sutradhar S., Sarkar P., Fantuzzi F., Ghosh B.N.
Journal of Photochemistry and Photobiology A: Chemistry, Elsevier, 2025